$DMAC News
Last published 3w ago
- 3w agoDMACDiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke TrialBusiness WireIndependent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-Estimation Interim Analysis Results Expected in Q1 2027 DiaMedica Therapeutics Inc.
- 3w agoDMACDiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader WebinarBusiness WireKey Opinion Leader Webinar on DM199 for Fetal Growth Restriction now Scheduled for November 24, 2026 Event to Include Results from First Two Phase 2 Early-Onset FGR Trial Cohorts DiaMedica Therapeutics Inc.
- 1mo agoDMACDiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR ResultsBusiness WireLeading Maternal-Fetal Medicine Experts to Discuss FGR Disease State, the Clinical Rationale for DM199 (Rinvecalinase Alfa) Early Safety and Trial Findings from First Cohort of Phase 2 Early-Onset FGR Trial to Be
- 2mo agoDMACDiaMedica Therapeutics to Participate in Upcoming September Investor ConferencesBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that
- 3mo agoDMACDiaMedica Therapeutics Second Quarter 2026 Financial Results and Business Update Conference Call - DIAMEDICA THERAPEUTICS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the Diomedica Therapeutics Second Quarter 2026 Earnings Conference Call. An audio recording of this webcast will be available shortly after the call today on Diomedca's
- 3mo agoDMACDiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business HighlightsBusiness WireEnrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September Positive Topline Results from Phase 2 Late-Onset
- 3mo agoDMACDiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026Business WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced
- 3mo agoDMACDiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on
- 4mo agoDMACDiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth RestrictionBusiness WireFirst clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatment DM199 is intended to improve maternal uterine artery blood
- 4mo agoDMACDiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical ProgramBusiness WireDiaMedica planning to conduct a rat pharmacokinetic and activity study, which it believes will address FDA-requested data for a preeclampsia IND DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage
- 5mo agoDMACDiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026Business WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the
- 5mo agoDMACDiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke TrialBusiness WireReMEDy2 Phase 2/3 AIS Trial of DM199 Surpasses 75% of Enrollment Required to Trigger Pre-Specified Interim Analysis Interim Analysis by Independent DSMB Expected to Determine if a Sample Size Re-Estimation (Ranging
- 6mo agoDMACDiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that its
- 6mo agoDMACDiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business HighlightsBusiness WireDM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Updated Dataset Expected 2Q 2026 ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpassed 70% of Required Interim Enrollment;
- 6mo agoDMACDiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026Business WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced
- 7mo agoDMACDiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business HighlightsBusiness WireReceived Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia. DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort
- 7mo agoDMACDiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026Business WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced
- 8mo agoDMACDiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in PreeclampsiaBusiness Wire"No Objection Letter" from Health Canada enables initiation of Phase 2 DM199 study in early-onset preeclampsia DM199 Preeclampsia program featured in recent National Public Radio (NPR) coverage DiaMedica
- 8mo agoDMACDiaMedica Therapeutics to Participate in Upcoming March Investor ConferencesBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that
- 10mo agoDMACDiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDABusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced
- 12mo agoDMACDiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business HighlightsBusiness WirePreeclampsia Phase 2 IST Trial: Part 1a Dose Escalation Cohort Complete with Expansion Cohort Now Enrolling; Screening for Part 3, Fetal Growth Restriction Cohort, Expected to Start in Coming Weeks Held in Person
- 1y agoDMACDiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in LondonBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that
- 1y agoDMACDiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025Business WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its third quarter 2025
- 1y agoDMACDiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireDiaMedica Therapeutics Inc.
- 1y agoDMACDiaMedica Therapeutics to Participate in Upcoming Investor ConferencesBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, today announced that
- 1y agoDMACDiaMedica Therapeutics to Participate in Cantor Global Healthcare ConferenceBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that
- 1y agoDMACDiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoDMACDiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business HighlightsBusiness WirePositive Phase 2 Interim Data Evaluating DM199 in Preeclampsia Showed Statistically Significant Reductions in Blood Pressure and Pulsatility Index as Well as No Placental Transfer $30 Million Private Placement
- 1y agoDMACDiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical OfficerBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the
- 1y agoDMACDiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025Business WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its second quarter 2025
- 1y agoDMACDiaMedica Therapeutics Announces Closing of $30.1 Million Private PlacementBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the
- 1y agoDMACDiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental TransferBusiness WireConference Call Today July 17, 2025 at 4:30 PM Eastern Time / 3:30 PM Central Time DM199 Demonstrated Highly Statistically Significant and Clinically Meaningful Reductions in Systolic and Diastolic Blood Pressure for
- 1y agoDMACDiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® IndexesBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member
- 1y agoDMACDiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025Business WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced that Rick Pauls, President and
- 1y agoDMACDiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of PreeclampsiaBusiness WireCompany to Host Preeclampsia Key Opinion Leader Event May 28, 2025 at 8 AM Eastern / 7 AM Central DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing a novel
- 1y agoDMACDiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025Business WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today a poster presentation of the safety and clinical
- 1y agoDMACDiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business HighlightsBusiness WireConference Call and Webcast May 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Topline DM199 Preeclampsia Phase 2 Part 1A Proof of Concept Results Expected in Near Term and Phase 2 Part 1B Expected to Initiate in
- 1y agoDMACDiaMedica Therapeutics to Participate in Upcoming Investor Conferences in MayBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming
- 1y agoDMACDiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025Business WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025
- 1y agoDMACDiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial ResultsBusiness WireConference Call and Webcast March 18 at 8:00 AM Eastern Time / 7:00 AM Central Time Preeclampsia Phase 2 Trial Preliminary Topline Safety and Efficacy Data from Part 1A of the Study Expected in the Second Quarter of
- 1y agoDMACDiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025Business WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its full-year 2024 financial results will
- 1y agoDMACDiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of DirectorsBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors,
- 1y agoDMACDiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal StrokeBusiness WireScientific insight into DM199's mechanism for increasing collateral circulation and salvaging brain tissue at-risk from infarction DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company
- 1y agoDMACDiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company's management will present at
- 1y agoDMACDiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of PreeclampsiaBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, is excited to announce the formation of its Scientific Advisory
- 1y agoDMACDiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoDMACDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial ResultsBusiness WireConference Call and Webcast Thursday November 14 at 8:00 AM Eastern Time / 7:00 AM Central Time Implemented Updates to AIS Program Intended to Enhance Probability of Trial Success and Expedite Study Completion, with
- 1y agoDMACDiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of PreeclampsiaBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that the first patient has been dosed in
- 2y agoDMACDiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select ConferenceBusiness WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company's management will attend the
- 2y agoDMACDiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024Business WireDiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its third quarter 2024 financial results